{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:31:02Z","timestamp":1790353862746,"version":"4.1.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to review the scientific evidence and describe the ocular treatment-emergent adverse events (TEAEs) related to pharmacological treatment in patients with multiple sclerosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic review of literature was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines in the MEDLINE, LILACS, EMBASE, and COCHRANE databases. Articles were filtered based on title and abstract considering the selection criteria and subsequently filtered by full-text reading. The resulting articles were evaluated using the Joanna Briggs Institute Quality Tools. Study characteristics and results were extracted and presented in structured tables to conduct a narrative synthesis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 2852 published articles were extracted using our strategy. After removing duplicates, 2841 articles were screened based on title and abstract, 102 articles were evaluated using quality tools, and 69 articles were filtered by full-text reading. Through this search strategy, 60 articles met all the inclusion criteria and seven articles, through a search update conducted in the same manner, were included. This resulted in 67 articles meeting the inclusion criteria, of which 11 were experimental and 56 were observational. The therapies related to ocular TEAEs were alemtuzumab, amantadine, fingolimod, steroids, CTLA-4 Ig, estriol, interferon \u03b2, natalizumab, hyperbaric oxygen, rituximab, siponimod, teriflunomide, and tovaxin. Fingolimod and siponimod were commonly associated with macular edema, interferon \u03b2 was associated with retinopathy, alemtuzumab was associated with thyroid eye disease, amantadine was associated with corneal edema, and steroids were associated with acute retinal necrosis. Opportunistic infections were also found, and there was one life-threatening case.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our search revealed different methodological assessments of the topic. However, longitudinal studies regarding ocular TEAEs related to multiple sclerosis therapy are necessary to provide evidence-based recommendations, especially in understudied regions such as Latin America and Africa. Physicians should monitor ocular symptoms in patients being treated for multiple sclerosis and consider an interdisciplinary approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Systematic review registration<\/jats:title>\n                <jats:p>PROSPERO ID CRD42020106886<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-021-01782-7","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T11:03:37Z","timestamp":1635419017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ocular adverse events from pharmacological treatment in patients with multiple sclerosis\u2014A systematic review of the literature"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9894-9323","authenticated-orcid":false,"given":"Juliana","family":"Mu\u00f1oz-Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2326-7213","authenticated-orcid":false,"given":"Juliana","family":"Reyes-Guanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-2877","authenticated-orcid":false,"given":"Estefan\u00eda","family":"Zapata-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-2486","authenticated-orcid":false,"given":"Laura","family":"Mora-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2711-0595","authenticated-orcid":false,"given":"Juan Antonio","family":"Reyes-Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1164-4656","authenticated-orcid":false,"given":"Luis Octavio","family":"Tierradentro-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-8989","authenticated-orcid":false,"given":"William","family":"Rojas-Carabali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-4201","authenticated-orcid":false,"given":"Marcela","family":"G\u00f3mez-Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-1989","authenticated-orcid":false,"given":"Alejandra","family":"de-la-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"issue":"3","key":"1782_CR1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1212\/CON.0000000000000737","volume":"25","author":"OH Kantarci","year":"2019","unstructured":"Kantarci OH. Phases and phenotypes of multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):636\u201354. https:\/\/doi.org\/10.1212\/CON.0000000000000737.","journal-title":"Continuum (Minneap Minn)."},{"issue":"3","key":"1782_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40265-017-0692-6","volume":"77","author":"G Heath","year":"2017","unstructured":"Heath G, Airody A, Gale RP. The ocular manifestations of drugs used to treat multiple sclerosis. Drugs. 2017;77(3):303\u201311. https:\/\/doi.org\/10.1007\/s40265-017-0692-6.","journal-title":"Drugs."},{"issue":"5","key":"1782_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/01.icu.0000179804.49842.e2","volume":"16","author":"L Chen","year":"2005","unstructured":"Chen L, Gordon LK. Ocular manifestations of multiple sclerosis. Curr Opin Ophthalmol. 2005;16(5):315\u201320. https:\/\/doi.org\/10.1097\/01.icu.0000179804.49842.e2.","journal-title":"Curr Opin Ophthalmol."},{"key":"1782_CR4","unstructured":"Safety Monitoring of Medicinal Products. Guidelines for setting up and running a Pharmacovigilance Centre. Uppsala Monitoring Centre - WHO Collaborating Centre for International Drug Monitoring, EQUUS, London, 2000. [Internet].\u00a0 \u00a0https:\/\/www.who.int\/healthpromotion\/about\/HPG\/en\/. Accessed4 May 2020."},{"issue":"9237","key":"1782_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(00)02799-9.","journal-title":"Lancet."},{"issue":"4","key":"1782_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139, W64. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135.","journal-title":"Ann Intern Med."},{"key":"1782_CR7","unstructured":"Joanna Briggs Institute Global. EPB Resources & Publications | Joanna Briggs Institute. 2021. [online] Available at: https:\/\/jbi.global\/ebp.\u00a0 Accessed 20 May 2021."},{"issue":"1","key":"1782_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1352458507079658","volume":"14","author":"HL Tremlett","year":"2008","unstructured":"Tremlett HL, Oger J. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Mult Scler. 2008;14(1):94\u2013105. https:\/\/doi.org\/10.1177\/1352458507079658.","journal-title":"Mult Scler."},{"key":"1782_CR9","doi-asserted-by":"publisher","unstructured":"Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545\u201356. https:\/\/doi.org\/10.1016\/S1474-4422(14)70049-3. Erratum in: Lancet Neurol. 2013 Jun;13(6):536.","DOI":"10.1016\/S1474-4422(14)70049-3"},{"key":"1782_CR10","doi-asserted-by":"crossref","unstructured":"Cohen J, Barkhof F, Comi G, Hartung H, Khatri B, Montalban X et al. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2010;362(5):402-415. [Internet]. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0907839.\u00a0 Accessed 5 May 2020.","DOI":"10.1056\/NEJMoa0907839"},{"key":"1782_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/1352458511428462","volume":"18","author":"E Fox","year":"2012","unstructured":"Fox E, Wynn D, Cohan S, Rill D, McGuire D, Markowitz C. A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design. Mult Scler. 2012;18:843\u201352.","journal-title":"Mult Scler"},{"issue":"10127","key":"1782_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30475-6.","journal-title":"Lancet."},{"key":"1782_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.msard.2016.11.002","volume":"11","author":"T Saida","year":"2017","unstructured":"Saida T, Kira JI, Kishida S, Yamamura T, Sudo Y, Ogiwara K, et al. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord. 2017;11:25\u201331. https:\/\/doi.org\/10.1016\/j.msard.2016.11.002.","journal-title":"Mult Scler Relat Disord."},{"issue":"8","key":"1782_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","volume":"12","author":"K Selmaj","year":"2013","unstructured":"Selmaj K, Li DKB, Hartung HP, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(13)70102-9.","journal-title":"Lancet Neurol."},{"issue":"6","key":"1782_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/1352458513507821","volume":"20","author":"P Vermersch","year":"2014","unstructured":"Vermersch P, Czlonkowska A, Grimaldi LME, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20(6):705\u201316. https:\/\/doi.org\/10.1177\/1352458513507821.","journal-title":"Mult Scler."},{"issue":"1","key":"1782_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(15)00322-1","volume":"15","author":"RR Voskuhl","year":"2016","unstructured":"Voskuhl RR, Wang H, Wu TCJ, Sicotte NL, Nakamura K, Kurth F, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(1):35\u201346. https:\/\/doi.org\/10.1016\/S1474-4422(15)00322-1.","journal-title":"Lancet Neurol."},{"issue":"12","key":"1782_CR17","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1212\/01.wnl.0000325915.00112.61","volume":"71","author":"V Viglietta","year":"2008","unstructured":"Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology. 2008;71(12):917\u201324. https:\/\/doi.org\/10.1212\/01.wnl.0000325915.00112.61.","journal-title":"Neurology."},{"issue":"12","key":"1782_CR18","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s10072-018-3550-8","volume":"39","author":"H Pakdaman","year":"2018","unstructured":"Pakdaman H, Abbasi M, Gharagozli K, Ashrafi F, Delavar Kasmaei H, Amini HA. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis. Neurol Sci. 2018;39(12):2107\u201313. https:\/\/doi.org\/10.1007\/s10072-018-3550-8.","journal-title":"Neurol Sci."},{"issue":"11","key":"1782_CR19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","volume":"18","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(19)30238-8.","journal-title":"Lancet Neurol."},{"issue":"1","key":"1782_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1001\/jamaophthalmol.2013.570","volume":"131","author":"AR Afshar","year":"2013","unstructured":"Afshar AR, Fernandes JK, Patel RD, Ksiazek SM, Sheth VS, Reder AT, et al. Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol. 2013;131(1):103\u20137. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.570.","journal-title":"JAMA Ophthalmol."},{"key":"1782_CR21","doi-asserted-by":"publisher","unstructured":"Akiyama H, Suzuki Y, Hara D, Shinohara K, Ogura H, Akamatsu M, Hasegawa Y. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report. Med (Baltim). 2016;95(29):e4180. https:\/\/doi.org\/10.1097\/MD.0000000000004180.","DOI":"10.1097\/MD.0000000000004180"},{"issue":"3","key":"1782_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.oftal.2012.07.020","volume":"89","author":"VM Asensio-S\u00e1nchez","year":"2014","unstructured":"Asensio-S\u00e1nchez VM, Trujillo-Guzm\u00e1n L, Ramoa-Osorio R. Cystoid macular oedema after fingolimod treatment in multiple sclerosis. Arch Soc Esp Oftalmol. 2014;89(3):104\u20136. https:\/\/doi.org\/10.1016\/j.oftal.2012.07.020.","journal-title":"Arch Soc Esp Oftalmol."},{"issue":"1","key":"1782_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3109\/08820538.2013.814693","volume":"30","author":"SJ Bakri","year":"2015","unstructured":"Bakri SJ, Swanson JW. Asymptomatic peripheral retinal hemorrhages as a manifestation of interferon beta 1a retinopathy. Semin Ophthalmol. 2015;30(1):56\u20137. https:\/\/doi.org\/10.3109\/08820538.2013.814693.","journal-title":"Semin Ophthalmol."},{"issue":"4","key":"1782_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/WNO.0b013e31829b42e1","volume":"33","author":"MT Bhatti","year":"2013","unstructured":"Bhatti MT, Freedman SM, Mahmoud TH. Fingolimod therapy and macular hemorrhage. J Neuroophthalmol. 2013;33(4):370\u20132. https:\/\/doi.org\/10.1097\/WNO.0b013e31829b42e1.","journal-title":"J Neuroophthalmol."},{"issue":"3","key":"1782_CR25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1001\/jamaneurol.2013.1960","volume":"70","author":"AL Boster","year":"2013","unstructured":"Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol. 2013;70(3):398\u2013402. https:\/\/doi.org\/10.1001\/jamaneurol.2013.1960.","journal-title":"JAMA Neurol."},{"issue":"3","key":"1782_CR26","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1097\/IOP.0000000000000774","volume":"33","author":"KL Christopher","year":"2017","unstructured":"Christopher KL, Elner VM, Demirci H. Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis. Ophthal Plast Reconstr Surg. 2017;33(3):e73\u20135. https:\/\/doi.org\/10.1097\/IOP.0000000000000774.","journal-title":"Ophthal Plast Reconstr Surg."},{"issue":"5","key":"1782_CR27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1001\/jamaophthalmol.2013.47","volume":"131","author":"J Chui","year":"2013","unstructured":"Chui J, Herkes GK, Chang A. Management of fingolimod-associated macular edema. JAMA Ophthalmol. 2013;131(5):694\u20136. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.47.","journal-title":"JAMA Ophthalmol."},{"issue":"4","key":"1782_CR28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1055\/s-0041-111803","volume":"233","author":"S de Massougnes","year":"2016","unstructured":"de Massougnes S, Borruat FX, Ambresin A. Peripheral bilateral telangiectasiae in multiple sclerosis patients treated with interferon b1a. Klin Monbl Augenheilkd. 2016;233(4):438\u201340. https:\/\/doi.org\/10.1055\/s-0041-111803.","journal-title":"Klin Monbl Augenheilkd."},{"issue":"3","key":"1782_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1600-0404.2005.00455.x","volume":"112","author":"L De Santi","year":"2005","unstructured":"De Santi L, Costantini MC, Annunziata P. Long time interval between multiple sclerosis onset and occurrence of primary Sj\u00f6gren\u2019s syndrome in a woman treated with interferon-beta. Acta Neurol Scand. 2005;112(3):194\u20136. https:\/\/doi.org\/10.1111\/j.1600-0404.2005.00455.x.","journal-title":"Acta Neurol Scand."},{"issue":"6","key":"1782_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/jop.2009.0029","volume":"25","author":"S Esquenazi","year":"2009","unstructured":"Esquenazi S. Bilateral reversible corneal edema associated with amantadine use. J Ocul Pharmacol Ther. 2009;25(6):567\u201370. https:\/\/doi.org\/10.1089\/jop.2009.0029.","journal-title":"J Ocul Pharmacol Ther."},{"issue":"3","key":"1782_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00415-015-7879-0","volume":"263","author":"L Gaetani","year":"2016","unstructured":"Gaetani L, Menduno PS, Cometa F, Di Gregorio M, Sarchielli P, Cagini C, et al. Retinopathy during interferon-\u03b2 treatment for multiple sclerosis: case report and review of the literature. J Neurol. 2016;263(3):422\u20137. https:\/\/doi.org\/10.1007\/s00415-015-7879-0.","journal-title":"J Neurol."},{"issue":"3","key":"1782_CR32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/WNO.0b013e31822bed20","volume":"31","author":"R Gallego-Pinazo","year":"2011","unstructured":"Gallego-Pinazo R, Espa\u00f1a-Gregori E, Casanova B, Pardo-L\u00f3pez D, D\u00edaz-Llopis M. Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosis. J Neuroophthalmol. 2011;31(3):292\u20133. https:\/\/doi.org\/10.1097\/WNO.0b013e31822bed20.","journal-title":"J Neuroophthalmol."},{"issue":"may12 1","key":"1782_CR33","doi-asserted-by":"publisher","first-page":"bcr2015210415","DOI":"10.1136\/bcr-2015-210415","volume":"2015","author":"JC-C Fan Gaskin","year":"2015","unstructured":"Fan Gaskin JC-C, Coote M. Postoperative cystoid macular oedema in a patient on fingolimod. BMJ Case Rep. 2015;2015(may12 1):bcr2015210415. https:\/\/doi.org\/10.1136\/bcr-2015-210415.","journal-title":"BMJ Case Rep"},{"key":"1782_CR34","doi-asserted-by":"publisher","first-page":"bcr-2016","DOI":"10.1136\/bcr-2016-218912","volume":"2017","author":"KM Jasani","year":"2017","unstructured":"Jasani KM, Sharaf N, Rog D, Aslam T. Fingolimod-associated macular oedema. BMJ Case Rep. 2017;2017:bcr-2016. https:\/\/doi.org\/10.1136\/bcr-2016-218912.","journal-title":"BMJ Case Rep"},{"issue":"9","key":"1782_CR35","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.ophtha.2008.03.011","volume":"115","author":"BH Jeng","year":"2008","unstructured":"Jeng BH, Galor A, Lee MS, Meisler DM, Hollyfield JG, Schoenfield L, et al. Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. Ophthalmology. 2008;115(9):1540\u20134. https:\/\/doi.org\/10.1016\/j.ophtha.2008.03.011.","journal-title":"Ophthalmology."},{"issue":"1","key":"1782_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00347-011-2448-0","volume":"109","author":"T Jenisch","year":"2012","unstructured":"Jenisch T, Dietrich-Ntoukas T, Renner AB, Helbig H, Gamulescu MA. Combined retinal artery and vein occlusions associated with interferon beta therapy. Ophthalmologe. 2012;109(1):71\u20135. https:\/\/doi.org\/10.1007\/s00347-011-2448-0.","journal-title":"Ophthalmologe."},{"issue":"4","key":"1782_CR37","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.survophthal.2015.12.008","volume":"61","author":"MJ Kim","year":"2016","unstructured":"Kim MJ, Bhatti MT, Costello F. Famous. Surv Ophthalmol. 2016;61(4):512\u20139. https:\/\/doi.org\/10.1016\/j.survophthal.2015.12.008.","journal-title":"Surv Ophthalmol."},{"issue":"1","key":"1782_CR38","first-page":"51","volume":"10","author":"GN Lambrou","year":"1987","unstructured":"Lambrou GN, Kopferschmitt J, Jaeger A, Brini A. Slowly reversible central scotoma: iatrogenic effect of hyperbaric oxygenation in the treatment of multiple sclerosis. J Fr Ophtalmol. 1987;10(1):51\u20139.","journal-title":"J Fr Ophtalmol."},{"issue":"1","key":"1782_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/08820530601182725","volume":"22","author":"R Longmuir","year":"2007","unstructured":"Longmuir R, Lee AG, Rouleau J. Cotton wool spots associated with interferon beta-1 alpha therapy. Semin Ophthalmol. 2007;22(1):49\u201353. https:\/\/doi.org\/10.1080\/08820530601182725.","journal-title":"Semin Ophthalmol."},{"issue":"8","key":"1782_CR40","doi-asserted-by":"publisher","first-page":"482","DOI":"10.33588\/rn.4008.2005132","volume":"40","author":"J Mallada-Frech\u00edn","year":"2005","unstructured":"Mallada-Frech\u00edn J, Abell\u00e1n-Miralles I, Alfaro-Beltra ML, Medrano V, Mu\u00f1oz-Gil MB, Fern\u00e1ndez-Izquierdo S, et al. Retinopathy secondary to treatment with interferon beta-1a in a patient with multiple sclerosis. Rev Neurol. 2005;40(8):482\u20134. https:\/\/doi.org\/10.33588\/rn.4008.2005132.","journal-title":"Rev Neurol."},{"issue":"6","key":"1782_CR41","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/jamaophthalmol.2013.2465","volume":"131","author":"A Minuk","year":"2013","unstructured":"Minuk A, Belliveau MJ, Almeida DRP, Dorrepaal SJ, Gale JS. Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use. JAMA Ophthalmol. 2013;131(6):802\u20134. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.2465.","journal-title":"JAMA Ophthalmol."},{"issue":"1","key":"1782_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2302\/kjm.58.54","volume":"58","author":"M Ohira","year":"2009","unstructured":"Ohira M, Ito D, Shimizu T, Shibata M, Ohde H, Suzuki N. Retinopathy: an overlooked adverse effect of interferon-beta treatment of multiple sclerosis. Keio J Med. 2009;58(1):54\u20136. https:\/\/doi.org\/10.2302\/kjm.58.54.","journal-title":"Keio J Med."},{"issue":"5","key":"1782_CR43","doi-asserted-by":"publisher","DOI":"10.3129\/i09-094","volume":"44","author":"JW Post","year":"2009","unstructured":"Post JW, Colleaux K. Interferon beta retinopathy in a patient with multiple sclerosis. Can J Ophthalmol. 2009;44(5):e37. https:\/\/doi.org\/10.3129\/i09-094.","journal-title":"Can J Ophthalmol."},{"key":"1782_CR44","doi-asserted-by":"publisher","unstructured":"Pul R, Osmanovic A, Schmalstieg H, Pielen A, Pars K, Schwenkenbecher P et al. Fingolimod associated bilateral cystoid macular edema\u2014wait and see? [Internet]. Int J Mol Sci. 2016;17(12) https:\/\/doi.org\/10.3390\/ijms17122106.","DOI":"10.3390\/ijms17122106"},{"issue":"5","key":"1782_CR45","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10792-010-9380-1","volume":"30","author":"AO Saatci","year":"2010","unstructured":"Saatci AO, Ayhan Z, Arikan G, Sayiner A, Ada E. Unilateral acute retinal necrosis in a multiple sclerosis patient treated with high-dose systemic steroids. Int Ophthalmol. 2010;30(5):629\u201332. https:\/\/doi.org\/10.1007\/s10792-010-9380-1.","journal-title":"Int Ophthalmol."},{"issue":"7","key":"1782_CR46","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1177\/1352458507077403","volume":"13","author":"H Saito","year":"2007","unstructured":"Saito H, Suzuki M, Asakawa T, Kato S. Retinopathy in a multiple sclerosis patient undergoing interferon-therapy. Mult Scler. 2007;13(7):939\u201340. https:\/\/doi.org\/10.1177\/1352458507077403.","journal-title":"Mult Scler."},{"issue":"11","key":"1782_CR47","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neurol.2008.11.019","volume":"165","author":"M Sallansonnet-Froment","year":"2009","unstructured":"Sallansonnet-Froment M, Roux X, de Greslan T, Bounolleau P, Taillia H, Ricard D, et al. Interferon-beta retinopathy. Rev Neurol (Paris). 2009;165(11):971\u20134. https:\/\/doi.org\/10.1016\/j.neurol.2008.11.019.","journal-title":"Rev Neurol (Paris)"},{"issue":"5","key":"1782_CR48","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.msard.2015.06.015","volume":"4","author":"K Schr\u00f6der","year":"2015","unstructured":"Schr\u00f6der K, Finis D, Harmel J, Ringelstein M, Hartung HP, Geerling G, et al. Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. Mult Scler Relat Disord. 2015;4(5):406\u20138. https:\/\/doi.org\/10.1016\/j.msard.2015.06.015.","journal-title":"Mult Scler Relat Disord."},{"issue":"10","key":"1782_CR49","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1212\/WNL.0000000000002450","volume":"86","author":"Z Sheikh","year":"2016","unstructured":"Sheikh Z, Jain S, Hillen M. Acute retinal necrosis in multiple sclerosis: A neuroimmunologic challenge! Neurology. 2016;86(10):972\u20133. https:\/\/doi.org\/10.1212\/WNL.0000000000002450.","journal-title":"Neurology."},{"issue":"5","key":"1782_CR50","first-page":"509","volume":"24","author":"S Sommer","year":"2001","unstructured":"Sommer S, Sablon JC, Zaoui M, Rozot P, Hosni A. Interferon beta-1b retinopathy during a treatment for multiple sclerosis. J Fr Ophtalmol. 2001;24(5):509\u201312.","journal-title":"J Fr Ophtalmol."},{"issue":"8","key":"1782_CR51","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/j.1442-9071.2011.02549.x","volume":"39","author":"O Spierer","year":"2011","unstructured":"Spierer O, Leibovitch I. Recurrent orbital inflammation in a patient with multiple sclerosis treated with interferon-beta. Clin Exp Ophthalmol. 2011;39(8):835\u20137. https:\/\/doi.org\/10.1111\/j.1442-9071.2011.02549.x.","journal-title":"Clin Exp Ophthalmol."},{"issue":"2","key":"1782_CR52","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1352458514528759","volume":"21","author":"S Thoo","year":"2015","unstructured":"Thoo S, Cugati S, Lee A, Chen C. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use. Mult Scler. 2015;21(2):249\u201351. https:\/\/doi.org\/10.1177\/1352458514528759.","journal-title":"Mult Scler."},{"issue":"6","key":"1782_CR53","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1097\/IOP.0000000000000310","volume":"32","author":"T Trinh","year":"2016","unstructured":"Trinh T, Haridas AS, Sullivan TJ. Ocular findings in alemtuzumab (Campath-1H)-induced thyroid eye disease. Ophthal Plast Reconstr Surg. 2016;32(6):e128\u20139. https:\/\/doi.org\/10.1097\/IOP.0000000000000310.","journal-title":"Ophthal Plast Reconstr Surg."},{"issue":"2","key":"1782_CR54","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00415-011-6367-4","volume":"259","author":"K Turaka","year":"2012","unstructured":"Turaka K, Bryan JS. Does fingolimod in multiple sclerosis patients cause macular edema? J Neurol. 2012;259(2):386\u20138. https:\/\/doi.org\/10.1007\/s00415-011-6367-4.","journal-title":"J Neurol."},{"issue":"1","key":"1782_CR55","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12886-015-0125-9","volume":"15","author":"N Ueda","year":"2015","unstructured":"Ueda N, Saida K. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report. BMC Ophthalmol. 2015;15(1):135. https:\/\/doi.org\/10.1186\/s12886-015-0125-9.","journal-title":"BMC Ophthalmol."},{"issue":"17","key":"1782_CR56","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1212\/WNL.0b013e3181bd114f","volume":"73","author":"C Zecca","year":"2009","unstructured":"Zecca C, Nessi F, Bernasconi E, Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurology. 2009;73(17):1418\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e3181bd114f.","journal-title":"Neurology."},{"issue":"3","key":"1782_CR57","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.nrl.2016.08.005","volume":"34","author":"P Cifuentes-Canorea","year":"2019","unstructured":"Cifuentes-Canorea P, Nieves-Moreno M, S\u00e1enz-Franc\u00e9s F, Santos-Bueso E. Edema macular precoz y recurrente en paciente en tratamiento con fingolimod. Neurolog\u00eda. 2019;34(3):206\u20137. https:\/\/doi.org\/10.1016\/j.nrl.2016.08.005.","journal-title":"Neurolog\u00eda."},{"issue":"1","key":"1782_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12948-020-00119-4","volume":"18","author":"R Husmann","year":"2020","unstructured":"Husmann R, Davies JB, Ghannam M, Berry B, Kelkar P. Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications. Clin Mol Allergy. 2020;18(1):3. https:\/\/doi.org\/10.1186\/s12948-020-00119-4.","journal-title":"Clin Mol Allergy."},{"issue":"1","key":"1782_CR59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.14310\/horm.2002.1501","volume":"14","author":"E Tsourdi","year":"2015","unstructured":"Tsourdi E, Gruber M, Rauner M, Blankenburg J, Ziemssen T, Hofbauer LC. Graves\u2019 disease after treatment with alemtuzumab for multiple sclerosis. Hormones (Athens). 2015;14(1):148\u201353. https:\/\/doi.org\/10.14310\/horm.2002.1501.","journal-title":"Hormones (Athens)"},{"issue":"2","key":"1782_CR60","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0161-6420(03)00663-8","volume":"111","author":"KE Williams","year":"2004","unstructured":"Williams KE, Johnson LN. Neuroretinitis in patients with multiple sclerosis. Ophthalmology. 2004;111(2):335\u201340; discussion 340-1. https:\/\/doi.org\/10.1016\/S0161-6420(03)00663-8.","journal-title":"Ophthalmology."},{"issue":"2","key":"1782_CR61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41433-018-0282-1","volume":"33","author":"JCP Roos","year":"2019","unstructured":"Roos JCP, Moran C, Chatterjee VK, Jones J, Coles A, Murthy R. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves\u2019 orbitopathy: a case series. Eye (Lond). 2019;33(2):223\u20139. https:\/\/doi.org\/10.1038\/s41433-018-0282-1.","journal-title":"Eye (Lond)."},{"issue":"6","key":"1782_CR62","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/1352458510394701","volume":"17","author":"C Holm\u00e9n","year":"2011","unstructured":"Holm\u00e9n C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011;17(6):708\u201319. https:\/\/doi.org\/10.1177\/1352458510394701.","journal-title":"Mult Scler."},{"issue":"2","key":"1782_CR63","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1017\/cjn.2015.325","volume":"43","author":"Y Lapierre","year":"2016","unstructured":"Lapierre Y, O\u2019Connor P, Devonshire V, Freedman MS, Kremenchutzky M, Yeung M, et al. Canadian experience with fingolimod: adherence to treatment and monitoring. Can J Neurol Sci. 2016;43(2):278\u201383. https:\/\/doi.org\/10.1017\/cjn.2015.325.","journal-title":"Can J Neurol Sci."},{"issue":"1","key":"1782_CR64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10072-016-2701-z","volume":"38","author":"A Laroni","year":"2017","unstructured":"Laroni A, Brogi D, Brescia Morra V, Guidi L, Pozzilli C, Comi G, et al. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. Neurol Sci. 2017;38(1):53\u20139. https:\/\/doi.org\/10.1007\/s10072-016-2701-z.","journal-title":"Neurol Sci."},{"issue":"3","key":"1782_CR65","first-page":"323","volume":"45","author":"RM Lisci\u0107","year":"2004","unstructured":"Lisci\u0107 RM, Brecelj J. Visual evoked potentials in multiple sclerosis patients treated with interferon beta-1a. Croat Med J. 2004;45(3):323\u20137.","journal-title":"Croat Med J."},{"issue":"10","key":"1782_CR66","doi-asserted-by":"publisher","first-page":"553","DOI":"10.5692\/clinicalneurol.cn-001074","volume":"57","author":"H Makioka","year":"2017","unstructured":"Makioka H, Nakaya F, Ling Y, Torii S, Saida T, Kira JI. Safety and effectiveness of interferon \u03b2-1a intramuscular therapy: results of the postmarketing drug surveillance in Japan. Rinsho Shinkeigaku. 2017;57(10):553\u201361. https:\/\/doi.org\/10.5692\/clinicalneurol.cn-001074.","journal-title":"Rinsho Shinkeigaku."},{"issue":"1\u20132","key":"1782_CR67","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jns.2012.09.009","volume":"323","author":"D Ontaneda","year":"2012","unstructured":"Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci. 2012;323(1\u20132):167\u201372. https:\/\/doi.org\/10.1016\/j.jns.2012.09.009.","journal-title":"J Neurol Sci."},{"key":"1782_CR68","doi-asserted-by":"publisher","unstructured":"Rommer PS, D\u00f6rner T, Freivogel K, Haas J, Kieseier BC, K\u00fcmpfel T, et al. Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a national online registry (GRAID). J Neuroimmune Pharmacol. 2016;11(1):1\u20138 https:\/\/doi.org\/10.1007\/s11481-015-9646-5, 1.","DOI":"10.1007\/s11481-015-9646-5"},{"issue":"8","key":"1782_CR69","doi-asserted-by":"publisher","first-page":"650","DOI":"10.18553\/jmcp.2015.21.8.650","volume":"21","author":"MY Smith","year":"2015","unstructured":"Smith MY, Sabid\u00f3-Espin M, Trochanov A, Samuelson M, Guedes S, Corvino FA, et al. Postmarketing safety profile of subcutaneous interferon beta-1a given 3 times weekly: A retrospective administrative claims analysis. J Manag Care Spec Pharm. 2015;21(8):650\u201360. https:\/\/doi.org\/10.18553\/jmcp.2015.21.8.650.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"1782_CR70","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","volume":"86","author":"O Tuohy","year":"2015","unstructured":"Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015;86(2):208\u201315. https:\/\/doi.org\/10.1136\/jnnp-2014-307721.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"4","key":"1782_CR71","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.purol.2016.10.005","volume":"27","author":"L Weglinski","year":"2017","unstructured":"Weglinski L, Manceau P, Thomas-Pohl M, Le Breton F, Amarenco G. Prospective evaluation of mouth and eye dryness induced by antimuscarinic drugs used for neurogenic overactive bladder in 35 patients with multiple sclerosis. Prog Urol. 2017;27(4):253\u201360. https:\/\/doi.org\/10.1016\/j.purol.2016.10.005.","journal-title":"Prog Urol."},{"issue":"9","key":"1782_CR72","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/1352458515614092","volume":"22","author":"MD Willis","year":"2016","unstructured":"Willis MD, Harding KE, Pickersgill TP, Wardle M, Pearson OR, Scolding NJ, et al. Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort. Mult Scler. 2016;22(9):1215\u201323. https:\/\/doi.org\/10.1177\/1352458515614092.","journal-title":"Mult Scler."},{"issue":"7","key":"1782_CR73","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ophtha.2012.12.040","volume":"120","author":"MA Zarbin","year":"2013","unstructured":"Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013;120(7):1432\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2012.12.040.","journal-title":"Ophthalmology."},{"key":"1782_CR74","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2147\/TCRM.S174864","volume":"14","author":"A Gugliandolo","year":"2018","unstructured":"Gugliandolo A, Longo F, Marrosu MG, Mancardi GL, Gandoglia I, Melis M, et al. A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients [Internet]. Ther Clin Risk Manag. 2018;14:1765\u201388. https:\/\/doi.org\/10.2147\/TCRM.S174864.","journal-title":"Ther Clin Risk Manag."},{"issue":"4","key":"1782_CR75","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10792-018-0870-x","volume":"39","author":"M Fruschelli","year":"2019","unstructured":"Fruschelli M, Capozzoli M, Gelmi MC, Masi G, Annunziata P. Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing\u2013remitting multiple sclerosis. Int Ophthalmol. 2019;39(4):777\u201381. https:\/\/doi.org\/10.1007\/s10792-018-0870-x.","journal-title":"Int Ophthalmol."},{"issue":"3","key":"1782_CR76","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ophtha.2018.10.013","volume":"126","author":"LL Lim","year":"2019","unstructured":"Lim LL, Silva DG, Lo TC, Pimentel RS, Butzkueven H, Hall AJ. Uveitis in patients with multiple sclerosis in clinical trials of fingolimod: incidence, prevalence, and impact on disease course. Ophthalmology. 2019;126(3):438\u201344. https:\/\/doi.org\/10.1016\/j.ophtha.2018.10.013.","journal-title":"Ophthalmology."},{"issue":"11","key":"1782_CR77","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (sunbeam): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009\u201320. https:\/\/doi.org\/10.1016\/S1474-4422(19)30239-X.","journal-title":"Lancet Neurol."},{"issue":"3","key":"1782_CR78","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2147\/tcrm.s5218","volume":"5","author":"BA Brown","year":"2009","unstructured":"Brown BA. Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag. 2009;5(3):585\u201394. https:\/\/doi.org\/10.2147\/tcrm.s5218.","journal-title":"Ther Clin Risk Manag."},{"issue":"9","key":"1782_CR79","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397.","journal-title":"N Engl J Med."},{"key":"1782_CR80","doi-asserted-by":"publisher","first-page":"i157","DOI":"10.1136\/bmj.i157","volume":"352","author":"L Zorzela","year":"2016","unstructured":"Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. https:\/\/doi.org\/10.1136\/bmj.i157.","journal-title":"BMJ."},{"key":"1782_CR81","unstructured":"Peryer G, Golder S, Junqueira D, Vohra S, Loke YK. Chapter 19: Adverse effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021.\u00a0 Available from https:\/\/www.training.cochrane.org\/handbook."},{"key":"1782_CR82","unstructured":"Management Sciences for Health and World Health Organization. Drug and Therapeutics Committee Training Course. Submitted to the U.S. Agency for International Development by the Rational Pharmaceutical Management Plus Program. Arlington: Management Sciences for Health; 2007."},{"issue":"2","key":"1782_CR83","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","volume":"11","author":"DH Miller","year":"2012","unstructured":"Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11(2):157\u201369. https:\/\/doi.org\/10.1016\/S1474-4422(11)70274-5.","journal-title":"Lancet Neurol."},{"key":"1782_CR84","doi-asserted-by":"publisher","unstructured":"Frohman TC, Graves J, Balcer LJ, Galetta SL, Frohman EM. The neuro-ophthalmology of multiple sclerosis. Continuum (Minneap Minn). 2010;16(5 Multiple Sclerosis):122\u201346 https:\/\/doi.org\/10.1212\/01.CON.0000389938.07532.67.","DOI":"10.1212\/01.CON.0000389938.07532.67"},{"key":"1782_CR85","unstructured":"Bomprezzi R, Powers JM. IFN-\u03b21b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. 2020. Accessed 5 May 2020. https:\/\/n.neurology.org\/content\/ifn%CE%B2-1b-may-severely-exacerbate-japanese-optic-spinal-ms-neuromyelitis-optica-spectrum."},{"issue":"6","key":"1782_CR86","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/ICU.0b013e328331913b","volume":"20","author":"JH Pula","year":"2009","unstructured":"Pula JH, Reder AT. Multiple sclerosis. Part I: Neuro-ophthalmic manifestations. Curr Opin Ophthalmol. 2009;20(6):467\u201375. https:\/\/doi.org\/10.1097\/ICU.0b013e328331913b.","journal-title":"Curr Opin Ophthalmol."},{"key":"1782_CR87","unstructured":"Andrew L. Ophthalmic screening recommendation for new MS drug. [online] The Ophthalmic News and Education Network. 2018. Available at: https:\/\/www.aao.org\/editors-choice\/ophthalmic-screening-recommendation-new-ms-drug. Accessed 20 May 2021."},{"issue":"8","key":"1782_CR88","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/BF03350193","volume":"11","author":"WM Wiersinga","year":"1988","unstructured":"Wiersinga WM, Smit T, van der Gaag R, Koornneef L. Temporal relationship between onset of Graves\u2019 ophthalmopathy and onset of thyroidal Graves\u2019 disease. J Endocrinol Invest. 1988;11(8):615\u20139. https:\/\/doi.org\/10.1007\/BF03350193.","journal-title":"J Endocrinol Invest."},{"issue":"7","key":"1782_CR89","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/14740338.2018.1483330","volume":"17","author":"AR Buonomo","year":"2018","unstructured":"Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2018;17(7):709\u201317.[Editor1]. https:\/\/doi.org\/10.1080\/14740338.2018.1483330.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-021-01782-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-021-01782-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-021-01782-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T11:16:56Z","timestamp":1635419816000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-021-01782-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1782"],"URL":"https:\/\/doi.org\/10.1186\/s13643-021-01782-7","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"assertion":[{"value":"8 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was performed according to the ethical principles for research involving human beings established by the Declaration of Helsinki, the Belmont Report, and Colombian Resolution 008430 of 1993. As it is a systematic review of the literature, it does not require approval by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}